Diagnosing and Assessing Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age
by Carsten Hamann, MD
Virtual (Zoom)
Learn more about the diagnosis and assessment of chronic spontaneous urticaria (CSU), including its clinical manifestations, diagnostic evaluation, assessment scales, and a treatment option for appropriate CSU patients 12+ years of age.
Exploring the Pathophysiology of Type 2 Inflammation in Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age
by Marshall Shuler, MD
Virtual (Zoom)
Learn more about the evolving understanding of the pathophysiology of chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate CSU patients 12+ years of age.
Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP)
by Timothy Patton, DO
Virtual (Zoom)
Learn more about the diagnosis and assessment of bullous pemphigoid (BP) including clinical manifestations, key laboratory investigations for diagnostic evaluation, consensus-based recommendations and a treatment option for appropriate BP patients.
Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Skin Diseases Driven in Part by Type 2 Inflammation
by Brian Bonomo, PA-C
Virtual (Zoom)
Learn more about itch in patients with atopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation.
Pathophysiology of Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age With Uncontrolled Moderate-to-Severe Atopic Dermatitis
by Amy Spizuoco, DO
Virtual (Zoom)
Learn more about the pathophysiology of atopic dermatitis (AD) and a treatment option that may help appropriate patients with uncontrolled moderate-to-severe atopic dermatitis.
Pathophysiology of Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age With Uncontrolled Moderate-to-Severe Atopic Dermatitis
by Jared Jagdeo, MD
Virtual (Zoom)
Learn more about the pathophysiology of atopic dermatitis (AD) and a treatment option that may help appropriate patients with uncontrolled moderate-to-severe atopic dermatitis.
Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP)
by Jenny Murase, MD
Virtual (Zoom)
Learn more about the diagnosis and assessment of bullous pemphigoid (BP) including clinical manifestations, key laboratory investigations for diagnostic evaluation, consensus-based recommendations and a treatment option for appropriate BP patients.
Diagnosing and Assessing Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age
by Gina Mangin, PA-C
Virtual (Zoom)
Learn more about the diagnosis and assessment of chronic spontaneous urticaria (CSU), including its clinical manifestations, diagnostic evaluation, assessment scales, and a treatment option for appropriate CSU patients 12+ years of age.
The Many Faces of Type 2 Inflammation: Unraveling Its Role Across Dermatologic Conditions and a Treatment Option for Appropriate Patients
by Jonathan Silverberg, MD
Virtual (Zoom)
Learn more about how Type 2 inflammation contributes to the clinical manifestations of atopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU); which cytokines play key roles in driving this activity; and a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation.
The Many Faces of Type 2 Inflammation: Unraveling Its Role Across Dermatologic Conditions and a Treatment Option for Appropriate Patients
by Zakiya Rice, MD
Virtual (Zoom)
Learn more about how Type 2 inflammation contributes to the clinical manifestations of atopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU); which cytokines play key roles in driving this activity; and a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation.